The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 12, 2012, Pages 1572-1579

  Horak, F ^a   Zieglmayer, P ^a   Zieglmayer, R ^a   Lemell, P ^a   Collins, L P ^b   Hunter, M G ^b   Steiner, J ^c   Lewis, T ^d   Payton, M A ^b   Perkins, C M ^b   Pettipher, R ^b  

^a Vienna Challenge Chamber   (Austria)

^b Oxagen Ltd   (United Kingdom)

^c Brightwell Cum Sotwell   (United Kingdom)

^d TLWise Consulting   (United Kingdom)

Author keywords

allergic rhinoconjunctivitis; CRTH2; OC000459; prostaglandin D2

Indexed keywords

ANTIALLERGIC AGENT; OC 000459; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINOCONJUNCTIVITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPIPHORA; EYE REDNESS; FEMALE; GRASS POLLEN; HUMAN; MALE; NASAL PRURITUS; NOSE OBSTRUCTION; NOSE SECRETION; OCULAR PRURITUS; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; RHINOMANOMETRY; RHINORRHEA; SNEEZING; TREATMENT DURATION;

ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; HUMANS; HYPERSENSITIVITY; INDOLEACETIC ACIDS; MALE; POACEAE; POLLEN; QUINOLINES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869495906     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12042     Document Type: Article

References (19)

1. Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38: 19-42.
2. Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF Jr, Meyers DA, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128: 597-602.
3. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193: 255-261.
4. 1 and CRTH2 in promoting allergic responses. Br J Pharmacol 2008; 153: S191-S199.
5. Gyles SL, Xue L, Townsend ER, Wettey F, Pettipher R,. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants. Immunology 2006; 119: 362-368.
6. Xue L, Barrow A, Pettipher R,. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol 2009; 156: 126-133.
7. 2 antagonist that inhibits mast cell-dependent activation of Th2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012; 340: 473-482.
8. 2 released from IgE/anti-IgE treated nasal polyp tissue. Allergy 2010; 65: 473-482.
9. Iliopoulos O, Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM,. Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 1992; 148: 2223-2228.
10. Bacon AS, Ahluwalia P, Irani AM, Schwartz LB, Holgate ST, Church MK, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 2000; 106: 948-954.
11. Guo CB, Liu MC, Galli SJ, Bochner BS, Kagey-Sobotka A, Lichtenstein LM,. Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 1994; 10: 384-390.
12. Nomiya R, Okano M, Fujiwara T, Maeda M, Kimura Y, Kino K, et al. CRTH2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice. J Immunol 2008; 180: 5680-5688.
13. 2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010; 638: 142-149.
14. Xue L, Barrow A, Pettipher R,. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2009; 182: 7580-7586.
15. Horak F, Stubner P, Zieglmayer R, Kavina A, De VC, Burtin B, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 73-79.
16. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P,. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005; 60: 24-31.
17. Zieglmayer UP, Horak F, Toth J, Marks B, Berger UE, Burtin B,. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus budesonide nasal spray in the management of nasal congestion in allergic rhinitis. Treat Respir Med 2005; 4: 283-287.
18. Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F,. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin 2008; 24: 1833-1840.
19. Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012; 42: 38-48.